Company profile
Matinas BioPharma Holdings, Inc.
AMEX:MTNBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OMEGA-3-PENTAENOIC ACIDS | phase3 | — | 1 | withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02310022 | phase1_2 | completed | 2014-11-01 | 2015-05-01 | Matinas Biopharma, Inc | A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules |
| NCT02629419 | phase2 | completed | 2016-09-27 | 2021-11-09 | Matinas BioPharma Nanotechnologies, Inc. | CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis |
| NCT03167957 | phase2 | withdrawn | 2019-12-01 | 2020-12-01 | Matinas BioPharma Nanotechnologies, Inc. | Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis |
| NCT03196921 | phase1_2 | withdrawn | 2018-10-01 | 2019-10-01 | Matinas BioPharma Nanotechnologies, Inc. | Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection |
| NCT04031833 | phase1_2 | completed | 2019-10-24 | 2022-11-14 | Matinas BioPharma Nanotechnologies, Inc. | Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) |
FDA applications (0)
No records yet.